Adding quetiapine to SRI in treatment-resistant obsessive-compulsive disorder: A randomized controlled treatment study

International Clinical Psychopharmacology

Volumn 20, Issue 4, 2005, Pages 223-226

  Fineberg, Naomi A ^a,b,c,d   Sivakumaran, Thanusha ^a   Roberts, Anne ^a   Gale, Tim ^a,b  

^a QUEEN ELIZABETH II HOSPITAL   (United Kingdom)

^b UNIVERSITY OF HERTFORDSHIRE   (United Kingdom)

^c IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Obsessive compulsive disorder; Quetiapine; Treatment resistant

Indexed keywords

CITALOPRAM; PAROXETINE; PLACEBO; QUETIAPINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG TOLERABILITY; ENDOCRINE DISEASE; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FEMALE; HEADACHE; HUMAN; MALE; MUSCLE STIFFNESS; OBSESSIVE COMPULSIVE DISORDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RESTLESS LEGS SYNDROME; SCORING SYSTEM; SEXUAL DYSFUNCTION; XEROSTOMIA; YALE BROWN OBSESSIVE COMPULSIVE SCALE SCORE;

ADULT; ANTIPSYCHOTIC AGENTS; DIBENZOTHIAZEPINES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; PLACEBOS; TREATMENT OUTCOME;

EID: 21244482555     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004850-200507000-00005     Document Type: Article

References (25)

1. American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th edn. Washington, DC: American Psychiatric Association.
2. Atmaca M, Kuloglu M, Tezcan E, Gecici O (2002). Quetiapine augmentation in patients with treatment-resistant obsessive compulsive disorder. A single blind, placebo-controlled study. Int Clin Psychopharmacol 17:15-119.
3. Barnes T (1989). A rating scale for drug-induced akathisia. Br J Psychiatry 154:72-676.
4. Bystritsky A, Ackerman DL, Rosen R, Vapnik T, Gorbis E, Maidment KM, et al. (2004). Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial. J Clin Psychiatry 65:565-568.
5. Denys D, van Megen H, Westenberg H (2002). Quetiapine addition to serotonin reuptake inhibitor treatment in patients with treatment refractory obsessive compulsive disorder; an open label study. J Clin Psychiatry 63:700-703.
6. Denys D, de Geus F, van Megen HJGM, Westenberg HGM (2004). A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive compulsive disorder refractory to serotonin reuptake inhibitors. J Clin Psychiatry 65:1040-1048.
7. Fineberg NA, Gale TM (2005). Evidence-based pharmacotherapy of obsessive compulsive disorder. Int J Neuropsychopharmacol 8:107-120.
8. Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, et al. (1989). The Yale-Brown Obsessive Compulsive Scale, I: development, use, and reliability. Arch Gen Psychiatry 46:1006-1011.
9. Guy W (1976). ECDEU Assessment Manual for Psychopharmacology, rev edn. Bethesda, Maryland: US Department of Health, Education and Welfare.
10. Hollander E, Rossi NB, Sood E, Pallanti S (2003). Risperidone augmentation in treatment-resistant obsessive compulsive disorder: a double-blind, placebo controlled study. Int J Neuropsychopharmacol 6:397-401.
11. Leckman JF, Riddle MA, Hardin MT, Ort SI, Swartz KL, Stevenson J, et al. (1989). The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity. J Am Acad Child Adolesc Psychiatry 28:566-573.
12. Leon AC, Shear MK, Portera L, Klerman GL (1992). Assessing impairment in patients with panic disorder: the Sheehan Disability Scale. Soc Psychiatry Psychiatr Epidemiol 27:78-82.
13. March JS, Frances A, Kahn DA, Carpenter D (1997). The Expert Consensus Guideline series: treatment of obsessive-compulsive disorder. J Clin Psychiatry 58 (suppl):1-72.
14. McDougle CJ, Goodman WK, Leckman JF, Lee NC, Heninger GR, Price LH (1994). Haloperidol addition in fluvoxamine-refractory obsessive-compulsive disorder: a double-blind placebo-controlled study in patients with and without tics. Arch Gen Psychiatry 51:302-308.
15. McDougle CJ, Epperson CN, Pelton GH, Wasylink S, Price LH (2000). A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor-refractory obsessive-compulsive disorder. Arch Gen Psychiatry 57:794-801.
16. Misri S, Milis L (2004). Obsessive-compulsive disorder in the postpartum: open-label trial of quetiapine augmentation. J Clin Psychopharmacol 24:624-627.
17. Mohr N, Vythilingum B, Emsley RA, Stein DJ (2002). Quetiapine augmentation of serotonin reuptake inhibitors in obsessive compulsive disorder. Int Clin Psychopharmacol 17:37-40.
18. Montgomery SA, Asberg M (1979). A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382-389.
19. Murphy DL, Pickar D, Alterman IS (1982). Methods for the quantitative assessment of depressive and manic behavior. In: Burdock EI, Sudilovsky A, Gershon S (editors): The Behavior of Psychiatric Patients: Quantitative Techniques for Evaluation. New York, New York: Marcel Dekker; pp. 355-392.
20. Pallanti S, Hollander E, Bienstock C, Koran L, Leckman J, Marazziti D, et al. (2002). Treatment non-response in OCD: methodological issues and operational definitions. Int J Neuropsychopharmacol 5:181-191.
21. Sevincok L, Topuz A (2003). Lack of efficacy of low dose quetiapine addition in refractory obsessive compulsive disorder. J Clin Psychopharmacol 23:448-450.
22. Simpson G, Angus J (1970). A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 212:S11-S19.
23. Toren P, Ratner S, Laor N, Weizman A (2004). Benefit-risk assessment of atypical antipsychotics in the treatment of schizophrenia and comorbid disorders in children and adolescents. Drug Saf 27:1135-1156.
24. Shapira NA, Ward HE, Mandoki M, Murphy TK, Yang MC, Blier P, et al. (2004). A double-blind placebo-controlled trial of olanzapine addition in fluoxetine-refractory obsessive compulsive disorder. Biol Psychiatry 55: 553-563.
25. Zohar J, Fineberg N (2001). Practical pharmacotherapy. In: Fineberg NA, Marazitti D, Stein D (editors): Obsessive Compulsive Disorder: A Practical Guide. London: Martin Dunitz.